April 25th 2024
The phase 2b findings support the capability of eftilagimod alpha to enhance the potential of immune checkpoint inhibitors in metastatic HNSCC.
Equalizing Inequities™ in Multiple Myeloma Care: Shining a Light on Current Barriers and Opportunities for Improved Outcomes
View More
Community Practice Connections™: Controversies and Conversations About HER2- Expressing Breast Cancer…Advances in Management of HER2-Low to -Positive Disease
View More
Community Oncology Connections™: Overcoming Barriers to Testing, Trial Access, and Equitable Care in Cancer
View More
Dialogues With the Surgeon on Integration of Systemic Therapies in Perioperative Settings for NSCLC: Looking at EGFR, ALK, IO, and Beyond…
View More
Tumor-Infiltrating Lymphocyte Therapy Advances Into Melanoma
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
Hanford I-131 Releases Did Not Increase Thyroid Cancer Risk
August 1st 2002WASHINGTON-Scientists have concluded that no increased risk of thyroid disease, including cancer, befell children exposed to Iodine-131 released from the Hanford Nuclear Weapons Production Facility in Washington State. According to
Current Approaches to the Treatment of Well-Differentiated Thyroid Cancer
March 1st 2002The increasing frequency of diagnosis and death of patients with follicular cell-derived carcinoma of the thyroid substantiates the need for a broad understanding of the optimal diagnostic and treatment strategies for this disease. Dr. Angelos has provided a good overview of the treatment modalities and approaches to follow-up for these patients. However, several points require additional emphasis or detail.
Current Approaches to the Treatment of Well-Differentiated Thyroid Cancer
March 1st 2002The management of well-differentiated thyroid cancer requires a multidisciplinary approach. The majority of patients are diagnosed only after a nodule is palpable. A cytologic evaluation can readily diagnose a papillary thyroid carcinoma but a follicular carcinoma requires determination of capsular or vascular invasion.
Current Approaches to the Treatment of Well-Differentiated Thyroid Cancer
March 1st 2002Well-differentiated thyroid cancer is something of an anomaly in the field of oncology for two primary reasons. First, the team of physicians who manage the patient consists primarily of endocrinologists, endocrine surgeons, and nuclear medicine physicians instead of medical oncologists, surgical oncologists, and radiation oncologists. Second, there is an extremely high rate of cure with remarkable 10- and 20-year survival rates due to the indolent nature of the tumor, even in the setting of lymph node metastases.
FDG-PET Detects Thyroid Cancer Better Than Conventional Imaging
December 1st 2001Fluorodeoxyglucose positron-emission tomography (FDG-PET) detected recurrent cancer 50% more often than did conventional imaging in people with thyroid cancer who had indications that their cancer had recurred, according to results of
Differentiated Thyroid Carcinoma: Risk Group Assignment and Management Controversies
In this review, we provide a framework for clinical decision-making in the treatment of differentiated thyroid cancer. The clinical discussion and treatment recommendations are relevant to an adult population (more than 16
FNA Identifies Follicular Variant of Papillary Thyroid Cancer
October 1st 1997SAN FRANCISCO-Fine-needle aspiration (FNA) may offer clinicians a partial solution to the problem of identifying follicular variants of papillary thyroid cancers, Larry Shemen, MD, said at the 101st Annual Meeting of the American Academy of Otolaryngology-Head and Neck Surgery. The traditional method of identifying follicular lesions, frozen section analysis, is often inconclusive, he noted. With the frozen section technique, the hallmark of this cancer-capsular or vascular invasion-may not be seen in the particular field studied, producing a false-negative result.
Thyroid Cancer Surgical Practice Guidelines
August 1st 1997The Society of Surgical Oncology surgical practice guidelines focus on the signs and symptoms of primary cancer, timely evaluation of the symptomatic patient, appropriate preoperative evaluation for extent of disease, and role of the surgeon in
Neck Check Exam Aims at Early Detection
March 1st 1997NEW YORK--Thyroid cancer is diagnosed in an estimated 15,600 Americans every year. As with many cancers, early detection is the key to effective treatment. Yet because thyroid cancer is asymptomatic, an enlarged thyroid or nodule on the gland is often the only sign that a malignancy is present.
Endocrinologists Issue Clinical Guidelines for Thyroid Cancer
March 1st 1997NEW YORK--Cancer of the thyroid, a highly treatable disease, is often overlooked in its earliest stages and, once diagnosed, may be treated too aggressively. In an effort to address these issues and to standardize treatment, the American Association of Clinical Endocrinologists (AACE) has published new guidelines for the management of thyroid carcinoma.
Thyroid Cancer Funds Go to New Jersey Center
September 1st 1995NEWARK, NJ--The Garden State Cancer Center has received a research grant of $605,000 from the FDA to develop a new treatment for medullary thyroid carcinoma. "The new therapy is based upon antibodies we have developed that target this cancer very selectively," said Dr. Malik Juweid, director of nuclear medicine and principal investigator on the grant.
Commentary (Cady): Management of Papillary Thyroid Cancer
February 1st 1995Dr. Vassilopoulou-Sellin begins her discussion advocating near total thyroidectomy with post-operation radiation iodine ablation for most patients. This is a thesis that can be questioned in terms of the numerous studies in recent years about risk